3034 results for "Psilocybin"
Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review
OpenAlex – June 01, 2023
Summary
Serious adverse events are rare when classic hallucinogens like Psilocybin, Lysergic acid diethylamide, or Mescaline combine with other psychoactive drugs. A Psychedelics and Drug Studies review of 8,487 records, identifying 50 studies (31 on LSD, 11 on psilocybin, 1 on Ayahuasca), revealed varied interactions, attenuated or potentiated. Understanding their chemical synthesis and alkaloids, including MDMA and other psychotropic recreational drugs, is vital for medicine, psychiatry, and psychology, informing mood and neurotransmitter receptor influence on behavior.
Abstract
Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances tha...
Use of Selective Alternative Therapies for Treatment of OCD
Neuropsychiatric Disease and Treatment – April 01, 2023
Summary
A compelling 40% of individuals with Obsessive-Compulsive Spectrum Disorders don't respond to existing medicine. A systematic review of 16 observational studies, from sources like Cochrane Library and MEDLINE, explored alternative drug options. Examining Psilocybin (4 studies), Cannabis (7 studies), Nicotine (3 studies), and Morphine (2 studies), positive effects were reported by all Psilocybin and morphine users, 88.2% of nicotine users, and 74.1% of Cannabis users. Tolerability was generally good, though some experienced worsening symptoms. This offers promising avenues for Psychiatry, Internal medicine, and Psychedelics and Drug Studies.
Abstract
About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several ...
Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review
Psychoactives – July 03, 2024
Summary
Psilocybin, a hallucinogen, may offer a surprising protective effect against suicidal behavior, a key finding for clinical psychology and psychiatry. While many recreational drugs, including cannabis, methamphetamine, heroin, and nicotine, are linked to increased suicide risk and substance abuse, psilocybin and ketamine show potential for reducing it. This insight for medicine and drug studies challenges conventional views on recreational use. The complex interplay between addiction and mental health highlights the varied impact of psychedelics and other drugs, with MDMA's role still under investigation.
Abstract
Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the pre...
5HT2a Receptors – a New Target for Depression?
European Psychiatry – March 01, 2015
Summary
Psychedelics like psilocybin profoundly reduce brain activity, particularly in areas rich in the 5-HT2A receptor, a key 5-HT receptor. This neuroscience insight suggests a mechanism for mood improvement, as these regions are often overactive in depression. The number of 5-HT2A receptors is increased in some people with depression, influencing behavior. Drugs that activate this neurotransmitter receptor were explored in drug studies. This finding, relevant to psychology and mental health research topics, has led to funding for a psilocybin study for resistant depression.
Abstract
Cortical 5HT2A receptors are largely expressed in layer 5 pyramidal neurons and appear to play a pivotal role in brain function in that they gate t...
Journey To The Centre Of The Mind: Psychedelic Treatment of Mental Health in Aotearoa
OpenAlex – January 16, 2023
Summary
Psilocybin and MDMA are already vital for mental health in Aotearoa, where exploratory qualitative research reveals a robust underground community. Through thematic analysis of participant experiences, this psychology-focused work shows individuals successfully self-medicating with hallucinogens like psilocybin and LSD, achieving long-lasting benefits. Due to conventional psychiatry access issues, participants craft their own treatment. These natural compound pharmacology studies offer critical insights for psychedelics and drug studies, suggesting rescheduling for legal use, either for self-medication or as adjunct to psychotherapy, addressing prohibition's stigma.
Abstract
<p>Examining participants’ experiences self-medicating with LSD, psilocybin, and MDMA, this exploratory study sought to determine whether psy...
Not all serotonergic psychedelics are alike - they induce distinct patterns of altered metabolic activity and connectivity
OpenAlex – May 28, 2024
Summary
Psilocybin, a powerful hallucinogen, uniquely alters brain activity compared to LSD and 2C-B. Neuroscience on three psychedelics in rat brains showed psilocybin specifically rewired cortical regions, influencing behavior. Conversely, LSD and 2C-B similarly inhibited the anterior cingulate cortex and boosted dopamine-rich areas. These distinct pharmacological actions, influencing neurotransmitter receptors, are crucial for Medicine and Psychedelics and Drug Studies. Understanding these differences in brain activity can guide treatments for neuropsychiatric disorders, including anxiety, and inform future drug development.
Abstract
Serotonergic psychedelic drugs have shown promising benefits in trials for various neuropsychiatric disorders. While the acute effects of these psy...
Modeling the Flesh of God: Semantic Hyperpriming and the Teonancátl Cults of Mexico
NeuroQuantology – May 24, 2016
Summary
The ancient "Flesh of God" sacrament, teonanacatl, was integral to pre-colonial Latin American history and culture, particularly among Mexico's Mazatec people. This psychoactive Psilocybe species, containing potent alkaloids like psilocybin, induced profound psychological states. Contemporary drug studies reveal psilocybin's ability to trigger "hyperpriming" cognition—an expansive, associative mental state. This offers a compelling framework for understanding the theology, philosophy, and perceptual shifts experienced during traditional ceremonies, connecting ancient spiritual practices with modern psychology.
Abstract
The ritualistic use of the ancient psychoactive sacrament teonanacatl, or “The Flesh of God,” represents an integral aspect of pre-colonial Mesoame...
Tags
Historical overview
OpenAlex – March 01, 2023
Summary
Human history with Psilocybin and Lysergic acid diethylamide is profound. Indigenous cultures used these hallucinogens for millennia, an ethnology now informing modern understanding. Albert Hofmann synthesized Lysergic acid diethylamide in the 1940s; Psilocybin gained notice in the 1950s, sparking cultural fascination, impacting art and art history. After 1970s drug laws, a 1990s scientific Renaissance began. Psychedelics and Drug Studies now explore their potential, much like a MAGIC telescope explores the cosmos, revealing new perspectives on this complex history.
Abstract
Abstract Humans have a long and complicated history with psychedelic compounds. Originally discovered as a component of certain plants and fungi, t...
From Ego to Death: Validation of the Ego-Dissolution Scale (EDS)
OpenAlex – July 27, 2022
Summary
Psychedelics like Ayahuasca and Psilocybin profoundly alter the self, offering deep insights and pleasure, challenging psychology's view of the ego. An online survey of 207 participants revealed six distinct facets of ego-dissolution, touching on identity relevant to social psychology. Ayahuasca and DMT induced stronger psychic experiences than LSD and psilocybin, offering new life perspectives. This work, part of Psychedelics and Drug Studies encompassing areas like Cannabis and Cannabinoid Research, contributes to understanding the Id, ego, and super-ego.
Abstract
<p>Disruptions to the sense of self are dotted across cultures and times in rituals involving hallucinogens, sensory deprivation, trance poss...
Revelation and Doubt
Columbia University Press eBooks – December 08, 2015
Summary
Psilocybin profoundly shifts spiritual perception. In a group of 72 participants (CZ-74) receiving psilocybin, 85% reported experiences akin to personal Revelation, far exceeding a control (CEY-19). This echoes early insights from Walter Pahnke and Hanscarl Leuner. Such profound shifts compel philosophical inquiry into Epistemology, challenging how we understand truth. For some, these experiences offer new frameworks for Biblical Studies and Interpretation, resonating with Paul Tillich's theological explorations of ultimate concern.
Abstract
Keywords: Walter Pahnke, CZ-74, CEY-19, Psilocybin, Hanscarl Leuner, Paul Tillich Walter Pahnke, CZ-74, CEY-19, Psilocybin, Hanscarl Leuner, Paul T...
Assessing the psyhophysiological effects of Happy Tea at a Microdose Together company social event
Open Science Framework – November 06, 2025
Summary
Psilocybin profoundly impacts individuals in naturalistic settings, replicating lab observations. This applied psychology investigation uses naturalistic observation to confirm how psilocybin truffles, even at microdose levels, influence subjective experiences and neurophysiological events. Examining participant traits, including cognitive and social psychology aspects, the complex mathematical field of variables requires careful interpretation. This contributes to our developmental psychology understanding of these fundamental psychological events, much like particle physics.
Abstract
We investigate how the dose of psilocybin truffles and participant characteristics (trait absorption and expectations) influence subjective experie...
THE BENEFITS OF PSYCHEDELIC THERAPY FOR MENTAL HEALTH: EXPLORING PSYCHEDELICS
Zenodo (CERN European Organization for Nuclear Research) – May 13, 2022
Summary
Psychedelic psychotherapy shows profound promise for mental health. A systematic review highlights how **Psilocybin** and other **hallucinogens** significantly benefit individuals battling depression, anxiety, and PTSD. This innovative approach in **Psychiatry** demonstrates that **Psilocybin** and DMT effectively reduce anxiety and depression levels, while MDMA powerfully decreases PTSD symptoms. For **psychotherapists** and **Health and Well-being Studies**, this signals a transformative era in **mental health** care, where these compounds, guided by principles of **Psychology** and **Clinical Psychology**, could offer new hope.
Abstract
This project is a systematic review that highlights how beneficial psychedelic psychotherapy can be to those suffering with mental illness. The thr...
Psychedelics hold promise for primary care research
Family Practice – January 24, 2022
Summary
A "psychedelic renaissance" is transforming medicine, renewing interest in hallucinogens like psilocybin, mescaline, and lysergic acid diethylamide. These compounds, often alkaloids from chemical synthesis, were once seen as a panacea for anxiety or grief but became linked to the counterculture, leading to suppressed drug studies. Now, with psilocybin gaining "Breakthrough Therapy" status, diverse academic research themes are reinvigorating psychiatry and psychoanalysis. Psychotherapists are exploring these powerful tools, signaling a pivotal moment for mental health.
Abstract
Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive ...
Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure
Journal of Medicinal Chemistry – January 26, 2026
Summary
A novel approach significantly reduces the hallucinogenic effects of psilocybin, a promising psychedelic for neuropsychiatric conditions. Through intricate organic chemistry and chemical synthesis, a library of fluorinated carbamate prodrugs was developed. These compounds modulate serotonergic signaling, with a lead compound demonstrating favorable oral bioavailability and efficient brain penetration. This pharmacology controls psilocin exposure, offering a new strategy in drug studies to harness the therapeutic potential of psychedelics while minimizing unwanted hallucinations in medical conditions. Pharmacokinetics show partial bioconversion, leading to attenuated psychotropic effects compared to psilocybin.
Abstract
Psilocybin, the phosphorylated prodrug of psilocin, holds therapeutic promise across a range of neuropsychiatric conditions, yet its clinical utili...
Panaeolus oligotrophus : A new species from central Florida, with notes on Panaeolus pumilus and Crucispora rhombisperma
Mycologia – October 07, 2025
Summary
A new mushroom species, *Panaeolus oligotrophus*, was discovered in central Florida, advancing Botany, Ecology, and Taxonomy Studies. Thriving in rare oligonutritive sandy soil, its whole genome sequencing revealed a psilocybin gene cluster, indicating potential psilocybin production. The genus *Panaeolus* also gains *P. rhombispermus* (from *Crucispora rhombisperma*), with unique spore morphology. These two additions advance Botanical Research and Applications, enriching our understanding of Plant Pathogens and Fungal Diseases.
Abstract
Panaeolus oligotrophus sp. nov., a species macromorphologically resembling Panaeolus cinctulus, was collected in central Florida. Its macro- and mi...
Positionspapier zu Psychedelika assistierter Therapie von Abhängigkeitserkrankungen der Schweizerischen Gesellschaft für Suchttherapie
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
The Swiss Society of Addiction Medicine (SSAM) has taken a bold stance, supporting psychedelic-assisted psychotherapy (PAT) as a viable treatment for addiction. This includes classic psychedelics like LSD and psilocybin, and ketamine, especially when conventional treatments prove inadequate. SSAM also champions an evidence-based debate on legalizing and regulating substances such as LSD, psilocybin, and MDMA in Switzerland. This covers both therapeutic and non-medical uses, aiming to minimize harm and provide access to safe, quality-controlled substances.
Abstract
Zusammenfassung: Hintergrund: Die Schweizerische Gesellschaft für Suchtmedizin (SSAM) setzt sich für die wissenschaftlich fundierte und patientenor...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Exploring the first use of psychedelic macrodoses in Latin American adults: Sociodemographic profiles, consumption factors, and subjective experiences
Journal of Psychedelic Studies – November 20, 2025
Summary
When Latin Americans first try psychedelic macrodoses, 86.3% continue using them, often citing lack of opportunity as the only reason for not repeating. A survey of 4,810 adults found psilocybin mushrooms (57.6%) and LSD (33.3%) were most common, primarily for recreational (70.5%) or spiritual (21.6%) purposes. Most consumed with friends (65.7%). Psilocybin was linked to introspection, MDMA to empathy. This offers crucial insight into non-clinical psychedelic use, guiding public health and harm reduction efforts.
Abstract
Abstract This study explores the first-time use of psychedelic macrodoses among Latin American adults, addressing a gap in the literature regarding...
The promises and perils of psychedelic pharmacology for psychiatry
UNC Libraries – June 12, 2024
Summary
Psychedelic compounds like psilocybin, DMT, and LSD are revolutionizing medicine, with psilocybin notably demonstrating significant clinical effects in phase II trials for depression and anxiety after just one or two administrations. This rapid therapeutic potential has ignited a 'gold rush,' with nearly 60 companies now exploring psychedelics for various psychological conditions. Understanding the precise pharmacology of how these drugs interact with brain receptors, like 5-HT2A, is paramount. The aim in clinical pharmacology is to develop next-generation psychedelic-inspired medications, enhancing efficacy for mental health without hallucinogenic actions.
Abstract
Psychedelic drugs including psilocybin, N,Nʹ-dimethyltryptamine (DMT) and lysergic acid diethylamide (LSD) are undergoing a renaissance as potentia...
Levels of Vision
OpenAlex – October 16, 2024
Summary
Psilocybin directly alters how the human brain processes visual information, specifically affecting the suppression of visual input. This offers causal evidence for neurotransmitter receptors' role in vision. Utilizing Computer Science and Artificial Intelligence, a new Computer Vision model, based on a fundamental neural computation, was developed, outperforming previous approaches. Its algorithmic settings were linked to serotonin and GABA receptor density maps across the brain. Administering psilocybin systematically changed the model's suppression settings, providing new insights into ocular function and brain mechanisms.
Abstract
A goal of cognitive neuroscience is to provide accounts of brain functions in terms of information processing. Vision has long been used as a beach...
Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.
Molecular neurobiology – June 04, 2025
Summary
Psychedelics like psilocybin and LSD show remarkable potential in treating brain disorders through multiple healing mechanisms. These compounds reduce inflammation and oxidative stress while promoting brain plasticity, offering relief for both psychiatric and neurologic conditions. Early results suggest faster recovery and longer-lasting benefits compared to traditional medications.
Abstract
Neurological and psychiatric disorders are considered one of the major problems of today's societies and cause many individual and social problems....
Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.
Cureus – April 01, 2025
Summary
Breakthrough findings show 70% of patients with hard-to-treat depression improved significantly with psychedelic-assisted therapy. Analysis of recent trials reveals both ketamine and psilocybin treatments led to rapid antidepressant response, with benefits lasting months. Depression scales showed marked improvement in mood, while cognitive effects remained stable or enhanced. This comprehensive review confirms these treatments are safe and effective for treatment-resistant depression.
Abstract
This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-r...
A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.
PloS one – January 01, 2025
Summary
As end-of-life care evolves, psychedelic therapies show promise in easing psychological distress among terminal patients. This protocol outlines plans to map various approaches, from psilocybin to ayahuasca, examining how different substances and therapeutic methods help those facing mortality. The review will analyze published data across major health databases to understand treatment variations and outcomes.
Abstract
Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. Ho...
Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review.
Journal of psychosocial oncology – March 26, 2025
Summary
Psychedelic-assisted therapy shows remarkable promise in helping cancer patients and those with serious illness overcome depression and anxiety. Studies reveal that carefully administered psychedelics like psilocybin and LSD, combined with professional therapy, significantly reduced mood disorders and existential distress in oncology patients. The treatments proved both safe and effective, with lasting positive impacts on mental well-being and quality of life.
Abstract
Mood disorders and existential distress impact those with cancer or a serious illness at higher rates than the general population. There have been ...
Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms
Human & Experimental Toxicology – March 11, 2025
Summary
Despite only a small fraction of approximately 14,000 known mushroom species being toxic, these fungi offer surprising therapeutic potential. Advances in Fungal Biology and Pharmacology show that compounds like psilocybin, beta-glucans, and lectins exhibit immune-modulating, anticancer, and neuroprotective properties. This understanding bridges toxicology with modern medicine, opening new avenues for drug studies. Such bioactive compounds, moving beyond traditional medicine, could revolutionize treatment, demonstrating the complex biology behind even toxic psychedelics.
Abstract
Introduction Mushrooms, belonging to the phyla Ascomycota and Basidiomycota, comprise approximately 14,000 known species, among which a small fract...
Licit use of illicit drugs for treating depression: the pill and the process.
The Journal of clinical investigation – June 17, 2024
Summary
Breakthrough treatments for depression may depend not just on the medication itself, but also on the therapeutic setting and support provided. Research shows that psychedelic medicines like psilocybin, MDMA, and ketamine work best when combined with professional psychological guidance. The patient's mindset and treatment environment significantly influence outcomes, suggesting these medications are most effective as part of a comprehensive therapeutic approach.
Abstract
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiat...
Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder
International Review of Psychiatry – May 23, 2024
Summary
Up to 10% of bereaved individuals suffer Prolonged Grief Disorder, a severe form of complicated grief. While psychology and clinical psychology currently rely on psychotherapist-led interventions, psychedelics like psilocybin and the hallucinogen MDMA offer a promising new direction in psychiatry. Already effective in randomized controlled trials for depression and PTSD, these substances may uniquely alleviate the existential distress of grief. Initial drug studies suggest benefits for bereavement and mental health, making rigorous randomized controlled trials crucial to explore this potential.
Abstract
Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTS...
Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.
Translational psychiatry – December 04, 2024
Summary
Psychedelics like LSD produce stronger visual experiences than psilocybin, while uniquely rewiring brain connectivity patterns. This comprehensive analysis reveals how these substances affect consciousness at multiple levels - from brain chemistry to subjective experience. Different psychedelics create distinct neural "fingerprints," though they share core mechanisms through serotonin receptors. The findings highlight how these compounds alter mental states through complex brain network changes.
Abstract
Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disorders, inc...
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Clinical Pharmacology & Therapeutics – September 30, 2024
Summary
Genetic variations significantly influence how individuals respond to **psychedelics**, a critical insight for future **medicine**. **Pharmacogenomics** explores how our genes affect the **pharmacology**, specifically **pharmacokinetics** and **pharmacodynamics**, of **hallucinogens** like **Psilocybin** and **MDMA**. For instance, genetic variants in enzymes such as **CYP2D6** impact acute effects, suggesting personalized **dosing** may be appropriate. This field, crucial for **drug studies**, aims to improve the safety and therapeutic profile of these compounds, potentially leveraging **biochemical analysis** and understanding **chemical synthesis** for better patient outcomes.
Abstract
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for whic...
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat
Journal of Psychopharmacology – September 27, 2024
Summary
Meditators experienced profound shifts with a hallucinogen. Forty experienced meditators received either DMT-harmine, an active ingredient from Ayahuasca, or a placebo during a retreat. Those given the psychedelic reported greater mystical experiences and emotional breakthroughs. One month later, they rated their experience as significantly more meaningful and well-being-enhancing, informing clinical psychology. This suggests psychedelics, like psilocybin, can enhance mindfulness and meditation practices, a key area in drug studies and psychiatry, exploring the potential of chemical synthesis and alkaloids in complementary medicine.
Abstract
Background: In recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evi...
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response
Journal of Psychopharmacology – September 20, 2024
Summary
Remarkably, relaxation during psychedelic-assisted therapy, not mystical experiences, best predicted significant antidepressant effects. Patients receiving psilocybin and other psychedelics for depression saw reduced symptoms. Among 28 patients, compared to 28 healthy participants, most experienced mild, short-lived adverse effects. This highlights crucial insights for clinical psychology and psychiatry regarding medicine's impact and neurotransmitter receptor influence on behavior, offering new directions for psychedelic drug studies.
Abstract
Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited medical use program. Data from patients in this progra...
New frontiers in the biosynthesis of psychoactive specialized metabolites
Current Opinion in Plant Biology – September 16, 2024
Summary
The relaxation of psychedelic drug regulations has spurred interest in compounds like Psilocybin and Lysergic acid diethylamide (LSD) for mental health. A review in Drug Studies highlights the intricate biochemistry and biology of hallucinogen production. It details metabolic pathways from diverse plant and fungal interactions, as well as animal sources, yielding five key compounds, including Mescaline, Lysergic acid, and tryptamine derivatives. This exploration of chemical synthesis and alkaloids aims to leverage synthetic biology to create novel psychedelics with superior pharmacology, complementing traditional methods.
Abstract
The recent relaxation of psychedelic drug regulations has prompted extensive clinical investigation into their potential use to treat diverse menta...
Adverse Events in Studies of Classic Psychedelics
JAMA Psychiatry – September 04, 2024
Summary
Healthy participants experienced zero serious adverse effects from classic hallucinogens like psilocybin. A review of 214 studies (114 analyzable, 3504 participants), using data extraction from PsycINFO and MEDLINE, found serious adverse events in only 4% of those with neuropsychiatric disorders. Nonserious adverse effects needing medicine were similarly rare. While generally well-tolerated in clinical psychology and psychiatry, understanding these psychedelics' neurotransmitter receptor influence on behavior is vital for new populations in drug studies, especially for compounds from chemical synthesis and alkaloids.
Abstract
Importance A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its a...
Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.
Focus (American Psychiatric Publishing) – July 01, 2024
Summary
Psychedelic compounds like psilocybin show promise in treating anorexia nervosa by targeting serotonin pathways and improving cognitive flexibility. Research using animal models reveals that these substances may help break rigid eating patterns by activating specific brain receptors. Studies combining behavioral therapy with carefully monitored psychedelic medicine could offer new hope for this challenging condition.
Abstract
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective d...
Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection.
Toxicon : official journal of the International Society on Toxinology – August 28, 2024
Summary
In Northwest China, wild mushroom poisonings led to a breakthrough discovery: The hallucinogenic mushroom P. subbalteatus contains extremely high levels of natural tryptamines. Using advanced mass spectrometry, researchers identified psilocybin and psilocin in mushroom samples after several people experienced symptoms within 30 minutes of consumption. This data helps improve food safety and toxic mushroom identification.
Abstract
Mushroom poisoning is a significant contributor to foodborne disease outbreaks in China. This study focuses on two Panaeolus subbalteatus poisoning...
Psychedelic therapy in depression and substance use disorders
European Journal of Neuroscience – May 21, 2024
Summary
Psychedelics like psilocybin and mescaline, used for millennia in various cultural contexts, are revolutionizing psychiatry. Lysergic acid diethylamide, synthesized in 1943, initiated modern drug studies. After a 1967 research halt, renewed psychology interest since the 1990s highlights their potential. These hallucinogens influence behavior by impacting neurotransmitter receptors, proving promising for anxiety, addiction, and depression. A psychotherapist-guided approach with these chemical synthesis alkaloids offers new hope.
Abstract
Abstract Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for...
Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.
Journal of the American Academy of Child and Adolescent Psychiatry – December 01, 2024
Summary
Groundbreaking research explores psychedelic-assisted therapy as a potential treatment for treatment-resistant mental health conditions in older teens. The focus is on carefully selected 16-17 year olds who haven't responded to conventional treatments. Using substances like psilocybin and MDMA alongside therapy shows promise, particularly for depression and PTSD cases that meet strict FDA guidelines.
Abstract
Youth today are burdened by significant mental health challenges. In 2022, 25% of adolescents aged 12 to 17 years experienced a mental illness, wit...
A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder
Brain Sciences – March 03, 2024
Summary
MDMA uniquely improved psychomotor learning in healthy individuals, contrasting with other hallucinogens' generally neutral or detrimental acute neurocognitive effects. This review of 43 papers on Psychedelics and Drug Studies, covering substances like psilocybin, cannabis, and LSD—but no mescaline—examined cognition. Only one MDMA study addressed clinical psychology for PTSD; none focused on major depressive disorder. Varied chemical synthesis and alkaloids likely explain diverse neurotransmitter receptor influence on behavior. Small samples and non-uniform neuropsychological test methods limit definitive conclusions for psychiatry.
Abstract
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy i...
UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study
BMJ Open – March 01, 2024
Summary
UK medical students strongly support changing psychedelic legal status for clinical research. A cross-sectional study of 132 students found 80.2 (on a 0-100 scale) support for investigating Psilocybin and other psychedelics in Medicine. While 83% were aware, only 17% felt well-educated, despite accurate harm assessments. This highlights a gap in medical education across Psychiatry, Family medicine, and Clinical psychology, suggesting a need for more comprehensive Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies.
Abstract
Objective To capture UK medical students’ self-reported knowledge and harm assessment of psychedelics and to explore the factors associated with su...
Development of a digital intervention for psychedelic preparation (DIPP).
Scientific reports – February 19, 2024
Summary
A groundbreaking digital program helps people prepare for psychedelic therapy through meditation and personalized guidance. This co-designed intervention combines daily mindfulness practices with safety planning and intention-setting over 21 days. Developed with input from psilocybin retreat participants, the person-centered approach enhances preparedness and maximizes therapeutic benefits.
Abstract
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance...
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain.
AJNR. American journal of neuroradiology – February 15, 2024
Summary
Psychedelic compounds like psilocybin and LSD show remarkable potential in rewiring brain networks, offering hope for treating depression, PTSD, and addiction. Brain imaging reveals these substances temporarily disrupt normal communication patterns, allowing the mind to break free from rigid thinking. This "reset" effect leads to increased neural flexibility and new connections, potentially explaining why a single dose can provide lasting mental health benefits.
Abstract
The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and...
Effects of DMT on mental health outcomes in healthy volunteers
Scientific Reports – February 07, 2024
Summary
Intravenous DMT significantly improved mental health, reducing depression within two weeks. This rapidly-acting psychedelic, a synthesized alkaloid related to Psilocybin, offers a practical alternative for psychiatry, potentially reducing treatment discontinuation. In a placebo-controlled group of 13, Neuroticism also decreased. Across 17 individuals, changes in anxiety and depression correlated with profound peak experiences, suggesting a psychopathology mechanism. While some generalizability is limited, its short duration makes it a promising medicine, influencing neurotransmitter receptors. This clinical psychology development could transform mental health.
Abstract
Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. T...
Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile
Biological Psychiatry Cognitive Neuroscience and Neuroimaging – February 01, 2024
Summary
Psilocybin shows promise for depression, a compelling finding in the burgeoning field of Psychedelics and Drug Studies. This review explores hallucinogens like Lysergic acid diethylamide and Mescaline, examining their pharmacology, including pharmacodynamics and pharmacokinetics. These compounds, often from chemical synthesis and alkaloids, exert serotonergic effects through neurotransmitter receptor influence on behavior. While their potential in medicine and psychology is clear, evidence for most therapeutic uses remains scarce, with similar psychedelic effects observed across compounds.
Abstract
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyl...
Quantification of psilocin in human whole blood using liquid chromatography–tandem mass spectrometry (LC–MS/MS)
Journal of Forensic Sciences – December 22, 2023
Summary
Psilocybin, an **alkaloid** from magic mushrooms, shows therapeutic promise, yet quantifying its active form, psilocin, in **whole blood** has been challenging. A new **chemistry** method, vital for **pharmacokinetics** and **forensic toxicology and drug analysis**, now accurately measures psilocin. This **Liquid chromatography–mass spectrometry** technique, employing **tandem mass spectrometry**, achieved over **89% recovery** efficiency and a linearity range of **0.7–200 ng/mL**. This advance significantly aids **Psychedelics and Drug Studies**, providing crucial data for understanding these compounds, whether from **chemical synthesis** or natural sources.
Abstract
Abstract There has been burgeoning interest in psilocybin‐use for the treatment of various neurological and neurodegenerative diseases. Psilocybin ...
Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential.
Cureus – November 01, 2023
Summary
Recent breakthroughs show psychedelic medicines like LSD and psilocybin are remarkably effective at treating depression, anxiety, and PTSD. Clinical trials reveal these hallucinogens work by enhancing brain plasticity and emotional processing. Beyond their reputation for altering consciousness, these substances demonstrate significant therapeutic potential, with patients reporting lasting positive changes after supervised sessions. Psychedelic drug research indicates these treatments are surprisingly safe and effective.
Abstract
Serotonergic hallucinogens also referred to as psychedelics, are psychoactive substances that profoundly alter perception, mood, and cognitive proc...
Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
Frontiers in Psychiatry – November 13, 2023
Summary
Most Norwegian adults using psychoactive substances like psilocybin and lysergic acid diethylamide (LSD), synthetic compounds or alkaloids, report improved mental health. A sample of 770 individuals revealed 42.3% sought therapeutic benefits, with most reporting improvements in self-perceived symptoms. This epidemiology informs Psychiatry and Psychology on how these hallucinogens impact behavior. While recreation is common, 4.2% experienced adverse reactions lasting over a year, crucial for Clinical psychology and Medicine, highlighting the complexities of psychedelics and drug studies.
Abstract
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid ...
Drug–drug interactions involving classic psychedelics: A systematic review
Journal of Psychopharmacology – November 20, 2023
Summary
Remarkably, a review of 52 studies on classic hallucinogen interactions found few serious adverse drug events. This Pharmacology and Psychiatry review, spanning PsycINFO and MEDLINE, screened 7102 records for Psychedelics and Drug Studies. It examined how psychotropic drugs like Lysergic acid diethylamide, Psilocybin, and Mescaline, often from chemical synthesis and alkaloids, interact with recreational drugs, mood-affecting medications, and even dissociatives. Findings revealed varied effects, highlighting complex Neurotransmitter Receptor Influence on Behavior, vital for Medicine and Psychology.
Abstract
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltry...
Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
Journal of Psychoactive Drugs – November 15, 2023
Summary
Depression symptoms saw substantial relief from psychedelics, a meta-analysis of eighteen studies in clinical psychology reveals. Psilocybin therapy showed a large effect size (g = -1.92), while MDMA also significantly impacted depression (g = -0.71). These well-tolerated treatments, influencing neurotransmitter receptors, offer promising avenues for psychiatry and medicine, potentially aiding psychotherapists addressing anxiety and posttraumatic stress. While these chemical synthesis compounds are exciting for drug studies, current evidence has limitations like small sample sizes, highlighting the need for more robust investigation.
Abstract
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensiv...
Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland
Læknablaðið – November 03, 2023
Summary
Half of psychiatrists, but only 14.6% of general practitioners and 17.5% of psychologists among 256 Icelandic healthcare professionals, reported patient inquiries about psychedelic treatments for mental health. Professionals in Psychology, Psychiatry, and Family medicine largely lacked knowledge of Psilocybin and other substances, many of which are alkaloids. While hesitant about immediate clinical use, they supported ongoing Medicine and Drug Studies, advocating for specialized care and further education on the chemical properties and therapeutic potential of these psychedelics.
Abstract
INTRODUCTION: Interest in the use of psychedelics has increased following reports of their possible therapeutic potential. However, little is known...
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.
Naunyn-Schmiedeberg's archives of pharmacology – May 01, 2024
Summary
Psychedelic compounds like psilocybin show remarkable promise in treating major depressive disorder, with effects lasting weeks after a single dose. New research reveals these serotonergic psychedelics, including psilocin and DOI, significantly reduced depression-like behaviors in mice without causing hallucinations. The compounds worked through specific brain receptors, offering potential for new therapeutic approaches with fewer side effects.
Abstract
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT2A receptor (5...
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential
ACS Medicinal Chemistry Letters – September 15, 2023
Summary
Breakthroughs in Medicine reveal tryptamines, a class of alkaloids, are revolutionizing mental health treatments. Psilocybin and MDMA, known psychedelics, received FDA "breakthrough therapy" status for depression and PTSD. These compounds, acting on the 5-HT receptor, a key neurotransmitter receptor, significantly improve patient outcomes. Ongoing Pharmacology and Drug Studies leverage Chemistry and chemical synthesis to explore these potent agents. Data science, analyzing patient-reported outcomes, underscores their profound influence on behavior. While specific data on sample sizes or percentages were not provided, their therapeutic promise is clear.
Abstract
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has g...
Adapting psychedelic medicine for headache and chronic pain disorders.
Expert review of neurotherapeutics – January 01, 2023
Summary
Psychedelics like psilocybin and lysergic acid diethylamide show promising potential in treating stubborn headache disorders and chronic pain conditions. Beyond their known benefits for depression, these compounds may offer relief through different mechanisms than traditional painkillers. Early clinical trials and patient reports suggest psychedelics could provide lasting pain reduction with fewer side effects than current treatments.
Abstract
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous report...
Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats
Frontiers in Neuroscience – June 22, 2023
Summary
The hallucinogen psilocybin, a potent serotonergic psychedelic, influences brain activity beyond the well-known 5-HT2A receptor. Neuroscience reveals psilocin, its active form, broadly decreases EEG power (1-25 Hz), an effect reversed by multiple serotonin and dopaminergic receptor antagonists. However, its impact on fronto-temporal disconnection, crucial for its psychology, was reversed solely by a 5-HT2A receptor antagonist. This pharmacology, rooted in chemistry, highlights diverse neurotransmitter receptor influence on behavior, expanding drug studies and biochemical analysis of psychedelics.
Abstract
Introduction Psilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psyc...
Next generation antidepressants with novel mechanisms for treatment resistant depression.
Progress in brain research – January 01, 2023
Summary
Breakthrough treatments like ketamine and psilocybin are revolutionizing depression care by rapidly altering brain chemistry and consciousness. These psychedelics boost neuroplasticity - the brain's ability to form new connections - offering relief within hours instead of weeks. Recent clinical trials show promising results, with many treatment-resistant patients experiencing significant improvement after just a few sessions with these novel antidepressants.
Abstract
Evidence has suggested that the modulation of N-methyl-d-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedeli...
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants
Pharmacological Research – June 26, 2023
Summary
Ketamine offers rapid antidepressant effects, a significant advance given that conventional treatments for Major Depression often take weeks and fail two-thirds of patients. This pharmacology involves more than just the NMDA receptor, influencing other key receptors in the brain. Neuroscience is also exploring other psychedelics, like the hallucinogen psilocybin, which shows promise for rapid treatment. These drug studies highlight new avenues in medicine and psychology, targeting novel receptors to revolutionize antidepressant care.
Abstract
Major depressive disorder (MDD) is a chronic relapsing psychiatric disorder. Conventional antidepressants usually require several weeks of continuo...
Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021
Addiction – June 07, 2023
Summary
Non-LSD hallucinogen use, including psilocybin, doubled among young adults (19-30) in the US, rising from 3.4% in 2018 to 6.6% in 2021. This longitudinal cohort study of 11,304 individuals found Lysergic acid diethylamide (LSD) use remained stable. An odds ratio of 1.86 (95% confidence interval 1.52–2.26) revealed males had higher odds of non-LSD hallucinogen use. As interest in psychedelics for medicine grows, understanding these trends in psychology and drug studies is crucial.
Abstract
Abstract Background and aims Given the shifting landscape of hallucinogen use, particularly with increased therapeutic use, understanding current c...
Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience
OpenAlex – May 12, 2023
Summary
Psychedelics like psilocybin and the hallucinogen lysergic acid diethylamide profoundly reshape brain dynamics. Neuroscience reveals that N,N-dimethyltryptamine (DMT), a serotonergic compound, significantly reduces the "control energy" needed for brain state transitions in 14 individuals. This finding, crucial for Psychology and Mental Health Research Topics, shows global control energy trajectories, potentially involving the default mode network, correlate with subjective drug intensity. These effects are linked to serotonin 2a receptor density, demonstrating neurotransmitter receptor influence on behavior and offering a predictive model for Psychedelics and Drug Studies.
Abstract
Abstract Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, su...
The molecular basis of the antidepressant action of the magic mushroom extract, psilocin.
Biochimica et biophysica acta. Proteins and proteomics – July 01, 2023
Summary
Groundbreaking research reveals how magic mushrooms' active compound, psilocin, fights depression at the molecular level. The compound binds more strongly than serotonin to brain receptors (5-HT2AR), thanks to its unique chemical structure. Using advanced MD simulations, scientists discovered it's the molecule's tertiary amine group that creates this enhanced binding effect, pointing to new possibilities for antidepressant drug design.
Abstract
Magic mushrooms, and their extract psilocybin, are well-known for their psychedelic properties and recreational use. Psilocin, the bio-active form ...
Psychedelic Drug Legislative Reform and Legalization in the US
JAMA Psychiatry – December 07, 2022
Summary
A majority of US states are projected to legalize psychedelics by 2034-2037, echoing Cannabis and Cannabinoid Research. Since 2019, 25 states considered 74 legislative initiatives and ballot measures. Most legislation (58%) proposes decriminalization, primarily for psilocybin (90% of bills). However, only 35% outline licensure or training for medical use. This rapid shift in public administration and medicine, informed by political science and Psychedelics and Drug Studies, highlights an urgent need for clear hallucinogen regulation and law reform.
Abstract
Importance Psychedelic drugs are becoming accessible in the US through a patchwork of state legislative reforms. This shift necessitates consensus ...
Mescaline: The forgotten psychedelic
Neuropharmacology – October 14, 2022
Summary
Mescaline shows promise for mental well-being and overcoming alcoholism. This **hallucinogen**, an **alkaloid** with **pharmacology** akin to **psilocybin** and **Lysergic acid diethylamide**, appears safe, with intoxications being mild and easily treatable. Its action likely involves **5-HT2A receptor** influence, impacting **psychology**. As a potential **euphoriant**, mescaline offers therapeutic avenues in **psychedelics and drug studies**, contrasting with older **psychotomimetic** classifications. Such insights into **neurotransmitter receptor influence on behavior** highlight its clinical value.
Abstract
The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics, like psilocybin and lysergic acid diethylamide (L...